Introduction
Alopecia areata (AA) is an autoimmune, nonscarring alopecic disorder with a lifetime
prevalence of about 2%.
1
This disorder presents with varying amounts of hair loss, ranging from focal patchy
loss to entire scalp and body hair loss as in alopecia totalis (AT) and alopecia universalis
(AU), respectively. Severe subtypes are difficult to treat and contribute to significant
patient burden. Current treatment strategies center on immunomodulation, both systemically
and topically.
Systemic therapies such as oral corticosteroids, cyclosporine, and methotrexate can
be efficacious, with regrowth rates between 30% and 76%.
2
However, side-effect profiles, lengthy treatment durations, and relapse rates after
discontinuation of therapy limit their use.
2
Newer Janus kinase (JAK) inhibitors appear promising, yet patients relapse after treatment
cessation, and cost is often prohibitive.
3
Topical glucocorticoids offer variable efficacy; 17.8% of patients with AT or AU had
long-term regrowth with clobetasol use.
4
Topical calcineurin inhibitors have not demonstrated efficacy, perhaps because of
insufficient depth of penetration.
5
Intralesional triamcinolone at concentrations of 2.5 to 5 mg/mL are considered first-line
therapy with regrowth seen in 61% of subjects with AT at 6 weeks and minimal side
effects.2, 6 An additional therapeutic option used for more severe forms of AA is
the topical immunomodulator, diphenylcyclopropenone (DPCP). Although the exact mechanism
of DPCP is unknown, its resultant allergic contact dermatitis is thought to cause
antigenic competition and an alteration of the inflammatory cytokine milieu.2, 7 In
one retrospective study of 50 patients treated with DPCP, terminal hair regrowth of
50% or more was seen in 56% and 71% of those with AU and AT, respectively.
7
Anthralin (dithranol), available in 0.25% to 1% concentrations, is another topical
treatment option. Anthralin functions via the production of a localized irritant dermatitis
with resultant pruritus, erythema, and scale. Patients who do not have a robust inflammatory
response to anthralin may not achieve significant therapeutic response.
2
Response rates with anthralin in AA and AT are between 25% and 75%.
2
Combination treatment strategies may provide a more robust therapeutic response, such
as the combination of minoxodil with topical glucocorticoids and anthralin with DPCP.2,
8
Calcipotriol/calcipotriene is a topical vitamin D3 analogue commonly used in plaque
psoriasis. Recently, a significant benefit of combination therapy with calcipotriol
and 5-fluorouracil has been identified in the treatment of actinic keratoses.
9
When used together, these medications show a synergistic mechanism of action, perhaps
because of calcipotriol's induction of antitumor immunity and allergic skin inflammation
via thymic stromal lymphopoietin cytokine.
9
The efficacy of this combination offers a potential corollary for the treatment of
additional dermatologic conditions in which immunomodulation plays a key role. The
combination of anthralin and calcipotriene may likewise demonstrate synergistic effects
in the treatment of AA.
Case report
A 39 year-old woman presented with a 20-year history of hair loss involving the scalp
and eyebrows. Her personal medical history was significant only for eczema, and she
had no family history of AA or other autoimmune disorders. The diagnosis of AA was
made by physical examination, which found diffuse patchy alopecia of the scalp without
erythema, scaling, or loss of follicular ostia (Figs 1 and 2). Near complete loss
of eyebrow hair was noted. Nail pitting was present.
Fig 1
Before therapy. Frontal and temporal scalp with patchy alopecic patches without loss
of follicular ostia.
Fig 2
Before therapy. Temporal, vertex and occipital scalp with patchy alopecic patches
without loss of follicular ostia.
She was previously treated with intralesional triamcinolone (2.5-5 mg/mL) over the
course of 5 years with minimal improvement. She was started on whole scalp anthralin
1% shampoo for 15 minutes nightly, increased to 90 minutes nightly for more than 2 months,
but she denied the development of any scalp irritation or regrowth. Next, a combination
of anthralin 1% cream with calcipotriene 0.005% cream was applied topically with duration
of application increased from 5 minutes to 90 minutes as tolerated for 5 days per
week. The anticipated side effect of scalp irritation with associated pruritus, erythema,
and scale then developed. Physical examination found increased hair density with background
scalp erythema. Eyebrow hair regrowth was not seen. Clinical response is illustrated
in Figs 3 and 4). The combination of anthralin and calcipotriene resulted in visible
hair regrowth with satisfactory cosmetic results that were maintained through follow-up
at 8 months. There were no adverse or unanticipated events.
Fig 3
After therapy. Frontal and temporal scalp with increased hair density. Mild erythema
and scaling of the scalp are seen.
Fig 4
After therapy. Temporal, vertex, and occipital scalp with increased hair density.
Discussion
We theorize that the combination of anthralin and calcipotriene promotes a robust
inflammatory response that may be useful in treatment-refractory AA. Anthralin functions
by inducing an irritant dermatitis, shifting T lymphocyte inflammation away from hair
follicles to the epidermis. It is well established that calcipotriene also causes
an irritant dermatitis; therefore, its concomitant use may bolster the resultant irritant
dermatitis, potentially hastening and/or amplifying clinical responses. However, calcipotriene
can also cause an allergic contact dermatitis, likely via expression of cytokine thymic
stromal lymphopoietin, which adds an additional mechanism of immunomodulation.9, 10
This patient's response can likely be attributed to combination therapy, as previous
treatment did not provide satisfactory regrowth, and diffuse AA is severe and thus
less likely to spontaneously remit. Further studies are needed to better understand
concomitant use of anthralin and calcipotriene in the promotion of hair regrowth in
AA, which may provide an attractive option for patients preferring topical over systemic
therapy.